Buntanetap (previously known as Posiphen) is a translational inhibitor of neurotoxic aggregating proteins. Different from monoclonal antibody therapies, buntanetap is an orally available small molecule with a unique mechanism of action that allows it to inhibit multiple neurotoxic proteins at once, including amyloid precursor proteins (APP), tau, αSYN, and TDP-43. Recent research has shown that multiple neurotoxic proteins are at play in all neurodegenerative diseases, and attacking only one protein has minimal effect.